-68.1%
RGTI vs MRNA
+945.0%
-1,013.2%
-71.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.1% | +13.1% | -12.0% | +0.6% |
| 7D | -9.6% | +20.6% | -30.2% | -10.3% |
| 30D | -26.0% | +27.1% | -53.2% | -26.7% |
| 3M | -35.8% | +353.4% | -389.1% | -41.7% |
| 6M | -36.7% | +446.3% | -482.9% | -47.8% |
| YTD | -49.4% | +776.2% | -825.6% | -66.1% |
| 1Y | -68.1% | +987.9% | -1,056.1% | -81.1% |
| All | -68.1% | +945.0% | -1,013.2% | -81.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling